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ABSTRACT To improve our understanding about the severity of invasive pneumo-
coccal disease (IPD), we investigated the association between the genotype of Strep-
tococcus pneumoniae and disease outcomes for 349 bacteremic patients. A pneumo-
coccal genome-wide association study (GWAS) demonstrated a strong correlation
between 30-day mortality and the presence of the phage-derived gene pblB, encod-
ing a platelet-binding protein whose effects on platelet activation were previously
unknown. Platelets are increasingly recognized as key players of the innate immune
system, and in sepsis, excessive platelet activation contributes to microvascular ob-
struction, tissue hypoperfusion, and ﬁnally multiorgan failure, leading to mortality.
Our in vitro studies revealed that pblB expression was induced by ﬂuoroquinolones
but not by the beta-lactam antibiotic penicillin G. Subsequently, we determined pblB
induction and platelet activation by incubating whole blood with the wild type or a
pblB knockout mutant in the presence or absence of antibiotics commonly adminis-
tered to our patient cohort. pblB-dependent enhancement of platelet activation, as
measured by increased expression of the -granule protein P-selectin, the binding of
ﬁbrinogen to the activated IIb3 receptor, and the formation of platelet-monocyte
complex occurred irrespective of antibiotic exposure. In conclusion, the presence of
pblB on the pneumococcal chromosome potentially leads to increased mortality in
patients with an invasive S. pneumoniae infection, which may be explained by en-
hanced platelet activation. This study highlights the clinical utility of a bacterial
GWAS, followed by functional characterization, to identify bacterial factors involved
in disease severity.
IMPORTANCE The exact mechanisms causing mortality in invasive pneumococcal
disease (IPD) patients are not completely understood. We examined 349 patients
with IPD and found in a bacterial genome-wide association study (GWAS) that the
presence of the phage-derived gene pblB was associated with mortality in the ﬁrst
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30 days after hospitalization. Although pblB has been extensively studied in Strepto-
coccus mitis, its consequence for the interaction between platelets and Streptococcus
pneumoniae is largely unknown. Platelets are important in immunity and inﬂamma-
tion, and excessive platelet activation contributes to microvascular obstruction and
multiorgan failure, leading to mortality. We therefore developed this study to assess
whether the expression of pblB might increase the risk of death for IPD patients
through its effect on enhanced platelet activation. This study also shows the value
of integrating extensive bacterial genomics and clinical data in predicting and un-
derstanding pathogen virulence, which in turn will help to improve prognosis and
therapy.
Streptococcus pneumoniae or the pneumococcus is a frequent colonizer of thenasopharynx. In a minority of carriers, infection progresses to pneumococcal dis-
ease, which leads to an estimated 1.6 million deaths annually (1, 2). The largest clinical
burden of invasive pneumococcal disease (IPD) is seen in young children and older
adults, who present mostly with sepsis and meningitis. Case mortality rates are esti-
mated to range from 11 to 30% in adults (3–5), with treatment becoming complicated
due to the worldwide emergence of multidrug resistance (6). Therefore, it is of utmost
importance to fully understand the pathogenic mechanisms of pneumococcal disease
in order to improve the treatment and prognosis of critically ill patients.
Recently, the utilization of whole-genome sequencing and analyses for predicting
and understanding pathogen virulence was highlighted (7). In this study, we performed
a genome-wide association study (GWAS) on 349 pneumococcal draft genomes of
blood isolates from patients who were admitted with IPD to two Dutch hospitals. We
identiﬁed a signiﬁcant association between 30-day mortality and the presence of pblB,
encoding a platelet binding protein that was also reported to function in adhesion (8).
In a subsequent functional study, we investigated the induction of phage-derived pblB
expression by ﬂuoroquinolones in S. pneumoniae. Lastly, we simulated in vivo condi-
tions using an ex vivo whole-blood assay demonstrating the importance of PblB in
enhancing platelet activation.
Platelets are an important part of the innate immune system and can interact with
and be activated by S. pneumoniae. In sepsis, platelet activation and platelet-leukocyte
complex (PLC) formation contribute to microvascular obstruction, tissue hypoperfusion,
and ﬁnally multiorgan failure (9). The role of this phage-derived gene in the clinical
outcomes of patients and the severity of their IPD, as well as the consequences of
platelet activation, warrant further study.
RESULTS
pblB is an independent determinant of 30-day mortality in IPD patients. We
conducted an unbiased association study for the presence or absence of pneumococcal
genes and mortality within the ﬁrst 30 days of hospitalization (Fig. 1A). Analysis was
performed on 349 sequenced pneumococcal isolates collected from a clinical IPD
cohort, which comprised strains from multiple lineages (10) (Fig. 1B). The GWAS was
stratiﬁed for population structure, and the sequence cluster membership as determined
by Bayesian analysis of population structure (BAPS) was used as a covariate in a
Cochran-Mantel-Haenszel (CMH) test (11). The overall 30-day mortality within this IPD
cohort was 11% (37/346; the outcome was unknown for 3 cases). We observed that of
the 1,946 orthologous genes (OGs) of the pneumococcal accessory genome, pblB
(OG_17) had a strong statistical correlation with 30-day mortality, with a Bonferroni-
corrected P value of 0.00034, and was present in 48% of the 349 clinical isolates.
We identiﬁed pblB as the phage-derived gene potentially most relevant to the
pathophysiology of IPD through its interaction with platelets, although it cooccurred
with other phage genes (see Table S1 in the supplemental material). Sequence exam-
ination of a representative clinical isolate, PBCN0103, revealed that two copies of pblB
were located within the same phage element next to OG_175 (holin) and OG_675
Tunjungputri et al. ®
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(hypothetical protein), both of which cooccurred with pblB and were also signiﬁcantly
associated with 30-day mortality (Fig. S1). In addition, OG_58, located in a phage
operon different than those of the aforementioned genes, is also signiﬁcantly associ-
ated with 30-day mortality (Table S1). Strikingly, these 4 OGs were present simultane-
ously in 168 out of 349 isolates (Fig. S2).
Among the IPD cases caused by pneumococci containing the pblB gene (pblB
strains), 27 out of 165 patients (16.4%) died within 30 days, compared to only 10 out
of 181 patients (5.5%) infected with strains not containing the pblB gene (pblB-negative
isolates) (P  0.0011; odds ratio [OR], 3.3). In a subanalysis of cases who died without
any limitations of medical treatment, 30-day mortality was 15/165 (9.1%) for those
infected with a pblB strain and 6/171 (3.3%) for those infected with a pblB-negative
strain, which remained statistically signiﬁcant (P  0.022; OR, 2.8). For all cases, the
presence of pblB was an independent determinant of 30-day mortality (OR, 3.4; 95%
conﬁdence interval [CI], 1.5 to 7.6), besides a Charlson comorbidity index score (OR, 1.5;
95% CI, 1.2 to 1.7) and a ﬁnding of meningitis (OR, 4.6; 95% CI, 1.6 to 13.7). For
pneumonia cases separately, in addition to the pneumonia severity index (PSI) score
(OR, 1.4; 95% CI, 1.1 to 1.7) and the Charlson comorbidity score (OR, 1.02; 95% CI, 1.01
to 1.04), both designed to predict mortality, the presence of pblB was an independent
risk factor for 30-day mortality (OR, 3.4; 95% CI, 1.2 to 9.5).
Fluoroquinolones induced the expression of pblB. It was unknown whether
pblB-containing temperate pneumophages are speciﬁcally induced by this group of
antibiotics in vitro. Therefore, different doses of ciproﬂoxacin (CPX) and levoﬂoxacin
(LVX), both belonging to the ﬂuoroquinolone group of antibiotics, mitomycin C (MitC),
and penicillin G (PenG; a beta-lactam antibiotic) were tested on three pblB-containing
pneumococcal strains (PBCN0103, PBCN0226, PBCN0239) in Todd-Hewitt broth supple-
mented with yeast extract (THY) to determine the sublethal doses of the four antibiotics
(data not shown). To conﬁrm that the selected doses were not bactericidal, the number
of CFU were determined after exposure to MitC, PenG, and the ﬂuoroquinolones for 2 h
at 37°C and 5% CO2 (Fig. S3). At the same time point, the difference in the levels of
expression of pblB and gyrA was measured. The DNA cross-linking agent MitC was
included as a positive control. Both the ﬂuoroquinolones, CPX and LVX (data not
shown), induced the expression of pblB, which appeared speciﬁc for this group of
antibiotics, as the beta-lactam antibiotic PenG did not induce its expression. Further-
more, strong variation was found between the different pneumococcal strains (Fig. 2).
FIG 1 (A) Flow chart of the computational method used to identify the association between the presence of orthologous genes (OGs) and 30-day mortality;
(B) phylogenic tree of the variable sites from the core genomes of all blood clinical isolates used in study. Phylogeny and sequence clustering were obtained
from the work of Cremers et al. (37). Pneumococcal clades are colored according to their sequence clusters (SCs). Information on serotypes is indicated in the
serotype legend. The ﬁlled red squares are those isolates that were derived from patients who died within 30 days of hospitalization. The pblB phage in our
cohort was not present in serotype 7F and only barely in serotype 1, as indicated by the green squares. Filled squares, present; open squares, absent. Red
indicates 30-day mortality. Dark green indicates the presence of pblB.
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Simulation of the clinical conditions in a whole-blood ex vivo assay. Of the 312
patients whose strains were sequenced and whose empirical treatment was known,
28% (n  88) received only a beta-lactam, 4% (n  11) received only ﬂuoroquinolones,
and 44% received a combination of a beta-lactam and a ﬂuoroquinolone. To simulate
the aforementioned clinical conditions, we incubated live pneumococcal strain
PBCN0162, containing a mutationally inactivated pblB gene (ΔpblB mutant), or the wild
type (WT) with and without antibiotics (PenG, CPX, and a combination of PenG and
CFX) in whole blood, determined the expression of pblB using quantitative PCR (qPCR)
(Fig. 3A), and measured in the same samples the activation of platelets. We were able
to measure pblB expression of the WT pneumococci in the whole-blood samples
without antibiotics (mean quantiﬁcation cycle [Cq] value, 30.6; 95% conﬁdence interval,
29.5 to 31.7) and its increase in the presence of antibiotics. We ﬁrst analyzed whether
the different antibiotics signiﬁcantly affected the WT- or ΔpblB bacterium-mediated
platelet activation state in whole blood using a liner mixed model. We found that in all
cases, stronger activation of platelets, together with higher platelet-monocyte complex
(PMC) formation, was observed with WT pneumococci than with the ΔpblB mutant,
which clearly indicates that PblB induces enhanced platelet activation irrespective of
the exposure to antibiotics (Fig. 3B).
While PenG did not strongly induce the expression of pblB in THY medium-grown
pneumococci (Fig. 2B), we observed PenG-dependent induction (~3-fold) of expression
in whole blood (Fig. 3A). This might be caused by an indirect effect, a consequence of
the bactericidal effect of PenG, leading to the production of reactive oxygen species
(ROS), which have DNA-damaging effects, inducing the expression of pblB. Despite the
fact that expression of pblB was much stronger in whole blood containing CPX, platelet
activation was not increased accordingly, indicating close-to-maximum activation un-
der these conditions.
DISCUSSION
In the present study, a GWAS was performed using the sequences of 349 S. pneu-
moniae invasive-disease isolates to test for associations between the presence or
FIG 2 Sublethal doses of antibiotics induced pneumococcal expression of the pblB phage in culture
medium. Induction of pblB expression after 2 h of incubation with sublethal doses of antibiotics was
determined in 4 different pneumococcal clinical isolate strains (PBCN0162, PBCN0239, PBCN0103, and
PBCN0226) by qRT-PCR by measuring levels of mRNA relative to the level of the control gene, gyrA. Data
presented are means with 95% conﬁdence intervals from three independent experiments.
Tunjungputri et al. ®
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absence of genes in the pneumococcal accessory genome and 30-day mortality. The
presence of the phage-borne pblB gene was positively associated with 30-day mortality
in patients with IPD. This ﬁnding suggested a role for pblB in pathogenesis and as the
expected cause of death of patients with IPD. The presence of the pblB phage gene as
a risk factor remained after adjustment for the local pneumococcal population structure
FIG 3 Live wild-type pneumococci in an ex vivo whole-blood assay showed increased expression of pblB
upon exposure to ﬂuoroquinolones and induced higher platelet activation than in the pblB knockout
mutant, irrespective of antibiotic exposure. Live pneumococci (strain PBCN0162) containing a mutation-
ally inactivated pblB gene (the ΔpblB mutant) or the wild type (WT pblB) were incubated in whole blood
in the presence or absence of penicillin G (PenG), ciproﬂoxacin (CPX), or a combination of both. After 2 h
of incubation at 37°C and 5% CO2, the expression of pblB was determined using qRT-PCR by measuring
levels of mRNA relative to those in the control samples. One extreme outlier value, as determined by
Grubbs’ test, in the CPX-exposed sample was excluded from panel A. Platelet expression of P-selectin,
platelet-ﬁbrinogen binding, and platelet-monocyte complex formation were measured in the same
samples using ﬂow cytometry and are expressed as percentages of positivity (B). Data presented are
means with 95% conﬁdence intervals from three independent experiments, with blood derived from a
total of 6 human volunteers.
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using BAPS. We therefore speculate that similar studies in other areas with different
pneumococcal populations would yield similar ﬁndings, although this requires conﬁr-
mation by other studies. The pblB phage in our cohort was not present in strains of
serotype 7F and only barely in strains of serotype 1, and these serotypes are associated
with a lower risk of death than other serotypes (12).
Past observations reported that 75% of pneumococcal clinical isolates carry bacte-
riophages (pneumophages) (13), which may be distributed among pneumococcal
isolates with different capsular serotypes, indicating that these mobile genetic ele-
ments are widely spread among clinically relevant pneumococcal strains (14). The
hypothesis that bacteria acquire virulence properties from phages is widely accepted
(15); however, there has been a paucity of data supporting the role of bacteriophages
in the pathogenesis of S. pneumoniae-caused diseases. Interestingly, pblB cooccurred
with two other genes in the phage element, one encoding a hypothetical protein and
the other encoding holin, both of which were also found to be signiﬁcantly associated
with 30-day mortality. The simultaneous cooccurrence of these genes in almost 50% of
our clinical isolates further indicates a functional link between PblB expression and
30-day mortality. The Holin protein is involved in the release of PblB and its mounting
to the bacterial surface of S. mitis (16), allowing PblB’s interaction with cells and the
propagation of platelet activation. Furthermore, PblB expression was also found to
contribute to virulence in an in vivo rabbit model of infective endocarditis (17). These
ﬁndings indicate that pblB has an important role in endovascular infection. In this
cohort, of all pblB-positive strains, 2.4% have 3 open reading frames (ORFs) annotated
as pblB, while 21.6% have 2 ORFs of various lengths annotated as pblB. In many
genomes, the shorter pblB fragments are all located at the ends of contigs. It is likely
either that these represent a single gene which has been fragmented due to an
~250-bp repeated sequence in the pblB gene or that the pblB gene is present in the
genome in multiple copies, both resulting in contig breaks. As all these genes are
annotated as pblB (OG_17), all were included in our association analysis.
Most patients in this cohort were treated with a combination of penicillin and
ciproﬂoxacin, which represented a common ﬁrst-line empirical antibiotic regimen for
severe community-acquired pneumonia in The Netherlands (18). We therefore pro-
ceeded with ex vivo experiments in which live pneumococci were incubated in whole
blood supplemented with penicillin or ciproﬂoxacin or a combination of the two to
simulate clinical conditions. The wild-type pneumococci clearly demonstrated en-
hanced platelet activation. Interestingly, there were differences in platelet activation
between knockout mutant and wild-type pneumococci even in the absence of high
pblB induction by the antibiotics. This may be explained by a constitutive expression of
pblB, which despite its low level was sufﬁcient to induce platelet activation, as has been
described for S. mitis (17).
S. pneumoniae has been shown to directly activate platelets, mainly through TLR2
(19), with FcRIIA and integrin IIb3 being involved in the ampliﬁcation of bacterium-
induced platelet activation (20). This leads to platelet degranulation and, subsequently,
to the release of an array of chemokines and inﬂammatory mediators which may
modulate not only their own function but also cells around them (21, 22). Our ﬁndings
that whole-blood exposure to WT pneumococci results in higher platelet activation
than does exposure to the pblB knockout mutant may explain why bacteremic patients
infected with pneumococci containing the pblB gene have a higher chance of dying
within 30 days. Approximately 20% increases from baseline values of platelet P-selectin
expression and of PMC have been associated with adverse cardiovascular events and
the acute phase of ischemic stroke (23, 24), and the increase in platelet activation
associated with pblB in our ex vivo assays exceeded the aforementioned value. By
causing enhanced platelet activation, bacteria can become engulfed in a septic throm-
bus and be protected from other cells of the immune system, allowing them to persist
in the circulation (25). We speculate that pblB-enhanced platelet activation may confer
this survival advantage to S. pneumoniae. On the other hand, the resulting excess of
platelet activation together with platelet clumping, platelet-leukocyte and platelet-
Tunjungputri et al. ®
January/February 2017 Volume 8 Issue 1 e01984-16 mbio.asm.org 6
 
m
bio.asm
.org
 o
n
 M
ay 15, 2017 - Published by 
m
bio.asm
.org
D
ow
nloaded from
 
endothelium aggregation, and increased ﬁbrin formation results in enhanced thrombo-
inﬂammatory responses, microvascular obstruction, tissue hypoperfusion, and ﬁnally
multiorgan failure in sepsis (26, 27). The increase in PMC formation predicts mortality
in older septic patients (28), and platelet consumption associated with platelet activa-
tion in sepsis patients leads to thrombocytopenia, which has been shown to increase
the risk of mortality (29–31). Autopsy was performed in only one case, which pointed
at a myocardial infarction as the cause of death. In one other case, myocardial infarction
was the most probable cause of death. In 16% of the cases, the cause of death was
described as being due to respiratory failure or septic shock as a consequence of the
primary diagnosis, and in the remaining cases, no cause of death was reported (32).
Our results have several potential clinical implications. First, we found that the
presence of pblB was an independent determinant of 30-day mortality, which illustrates
that a bacterial GWAS potentially identiﬁes intraspecies variation related to clinical risks
associated with human infection. Knowledge of the bacterial genotype might improve
clinical management by increasing alertness for a particular disease manifestation, in
this case, diffuse intravascular coagulation in pblB-positive IPD patients. However, as
disease manifestations are generally the product of multiple covariates, the contribu-
tions of bacterial genotypes may vary across clinical settings. Second, our results
demonstrated that ﬂuoroquinolones induce high pblB expression. However, the pres-
ence of ﬂuoroquinolones was not required by the pblB-expressing wild-type pneumo-
cocci to enhance platelet activation compared with that of the knockout mutant. Given
that ﬂuoroquinolones are frequently used in the management of community-acquired
pneumonia for the coverage of atypical pathogens (33), sufﬁciently powered studies
are needed to investigate the clinical outcomes of the interplay between the antibiotic
regimen and pblB presence before drawing any conclusions. Third, our study further
highlights the importance of platelet-bacterium interaction and platelet activation,
both in providing a survival advantage for bacteria and in posing an increased risk of
mortality in patients. There are more and more data on the use of platelet function
inhibitors in sepsis; however, these results at times contradict one another (9). Platelet
inhibition by the P2Y12 receptor antagonists reduces the release of proinﬂammatory
mediators from the platelet -granules (34). Taken together with our ﬁndings, the
ﬁnding of a beneﬁt of antiplatelet agents as adjunctive therapy in sepsis warrants
further investigation.
The limitation of our study is the paucity of information on PblB protein expression
on the pneumococcal surface. Previously, PblB of S. mitis was shown to function in
adhesion by interacting with 2,8-linked sialic acid residues on platelet membrane
gangliosides (35). More recently, Hsieh and colleagues showed that pblB knockout
mutant pneumococci had decreased adherence to respiratory epithelial cells and
platelets (8). Our study also adds to the research by showing that pblB may have
additional effects, as we observed, on platelets in the bloodstream. Further work to
demonstrate pneumococcal pblB expression at the protein level, as well as to identify
its binding domain on platelets, is needed. The original objective of this study was to
identify the association between the pneumococcal accessory genomes of the clinical
isolates and the recorded clinical phenotypes of the patients. We cannot ascertain the
cause of death for all patients who died, as it was not reported in the majority of cases
and autopsy was performed in only one case. To the best of our knowledge, this is the
only patient-based study which reveals the role of pblB gene expression in the
pathogenesis of IPD based on an extensive analysis of both bacterial genomics and
clinical data; it independently adds substantial evidence to only two previous studies
on pneumococcal pblB in vitro and in mice (8, 36).
In conclusion, we have integrated genome sequencing and a GWAS with functional
characterization to investigate the clinical role of pblB’s presence in the mortality of
patients with IPD. A bacterial GWAS may be an important tool to study the potential
predictive value of certain virulence genes. As genomic sequencing is increasingly
being utilized, we believe that this integrated approach will assist greatly in elucidating
pblB and Platelet Activation in Pneumococcal Disease ®
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the mechanisms of bacterial pathogenesis, leading to the development of novel
diagnostics and new therapeutic approaches.
MATERIALS AND METHODS
Study population. Consecutive patients hospitalized with a bacteremic pneumococcal infection at
two Dutch hospitals between 2001 and 2011 were included in the study. Detailed clinical data were
obtained on patient characteristics, clinical severity, treatment, and the course of disease. Corresponding
blood culture isolates of S. pneumoniae were collected and serotyped as described before (10). For 349
of the isolated strains, sequencing, assembly of draft genomes, and annotation were done as previously
described (37). This study was reviewed and approved by local medical ethical committees. All adult
patients and healthy volunteers involved in this study provided written informed consent.
Orthologous clustering and the GWAS. Orthologous genes (OGs) from S. pneumoniae used in this
study have previously been described by our group (37). Putative protein coding sequences were
investigated using an “all-versus-all” protein BLAST (BLASTp), with a 10e15 E value cutoff and a
BLOSUM90 substitution matrix. The results were subsequently categorized into clusters of orthologous
groups using TribeMCL (37, 38), resulting in a total of 3,021 OGs, 1,075 of which were conserved in all
isolates in a single copy. The population (sub)structure (sequence clusters [SCs]) used for population
stratiﬁcation in the study have also been previously characterized (37). We based disease severity on
mortality within the ﬁrst 30 days of admission to the hospital and categorized the pneumococcal isolates
into three groups: isolates derived from patients who died (n  37), from patients who survived (n 
309), and from patients from whom the data were not captured (n  3). The Cochran-Mantel-Haenszel
(CMH) association statistics were employed to test the associations between the presence or absence of
pneumococcal OGs and 30-day mortality, conditional on the bacterial population substructure as
proposed by Bayesian analysis of population structure (BAPS; analysis 11). All associations were deter-
mined using PLINK (39). Candidate OGs were selected based on an association test with a P of 0.05
(with Bonferroni adjustment for multiple testing). Results were visualized using ITOL (40).
Adjustment for covariates of mortality. Potentially interesting covariates of 30-day mortality were
analyzed using binary logistic regression analysis by likelihood ratio-based backward modeling; the
pneumococcal OG and identiﬁed possible covariates were entered as explaining variables. Detailed
statistical methods are described in Text S1 in the supplemental material.
Induction of pblB expression by antibiotics. Three isolates randomly selected from the group of
deceased patients, containing the pblB gene, were selected: PBCN0103, PBCN0226, and PBCN0239.
Different concentrations of mitomycin C, penicillin G, ciproﬂoxacin, and levoﬂoxacin (all purchased from
Sigma-Aldrich, Zwijndrecht, The Netherlands) were tested to determine the sublethal doses. The pneu-
mococci were grown in THY medium to mid-log phase (optical density [OD], 0.3) and then diluted to an
OD of 0.1, supplemented with 0.132 g/ml mitomycin C, 0.0125 g/ml penicillin G, 0.533 g/ml
ciproﬂoxacin, or 0.533 g/ml levoﬂoxacin, and grown for an additional 2 h at 37°C with 5% CO2.
Subsequently, serial dilutions were incubated on blood agar plates (BD) and incubated overnight at 37°C
with 5% CO2. Experiments were performed in triplicate to determine the expression of pblB. Mitomycin
C was included as a positive control, as it was previously shown to induce pblB expression (41). After 2 h
of growth, pneumococci were harvested by centrifugation. The supernatant was discarded, and a
2:1 volume of RNA Protect (Qiagen, Hilden, Germany) was added to the pellet. RNA was isolated using
the RNeasy kit (Qiagen, Hilden, Germany) by following the manufacturer’s instructions. Residual DNA was
removed with a DNase treatment using the Ambion Turbo DNA-free kit according to the manufacturer’s
instructions (Ambion, Austin, TX). The qRT-PCR was performed as previously described by DeBardeleben
et al. (41) using the following primers: HBgyrAF, AATGAACGGGAACCCTTGGT, HBgyrAR, CCATCCCAACC
GCGATAC, pblB_F, TACAGCTGTGAAAGCCTTGG, and pblB_R, GATAGCCATCTGGATTCTCAGG.
Construction of S. pneumoniae strain PBCN0162pblB. A directed gene deletion mutant of
S. pneumoniae strain PBCN0162 was generated by allelic exchange of the target gene (pblB) with a
spectinomycin resistance cassette (obtained from pR412T7), using the megaprimer PCR method; this
resulted in PBCN0162ΔpblB. Brieﬂy, ﬂanking regions of ~500 bp, containing less than 150 bp of the
coding sequence of the target genes, were ampliﬁed by PCR, with chromosomal DNA as the template.
For each ﬂanking region, the primer closest to the target gene (extension plus _L2 or _R2) contained an
additional sequence complementary to primer PBpR412_L or PBpR412_R. In a second PCR, the PCR
products of the two ﬂanking regions and the antibiotic resistance cassette were combined, leading to
incorporation of the antibiotic resistance cassette between the two ﬂanking regions of the target gene,
as previously described by Burghout et al. in 2007 (42). The primer sequences are provided in Table S2
in the supplemental material. Subsequently, the megaprimer PCR product was used for transformation
of competent PBCN0162. Mutants, selected on blood agar plates containing spectinomycin, were
assessed by colony PCR for recombination at the desired location on the chromosome. Chromosomal
DNA was isolated from the mutants and used for transformation of competent strain PBCN0162. Gene
inactivation was conﬁrmed by quantitative real-time PCR gene expression analyses as described above
(see “Induction of pblB expression by antibiotics”).
Ex vivo (whole-blood) assays. Whole blood was obtained from healthy volunteers (n  6) after
informed consent using tubes anticoagulated with 3.2% citrate (BD Vacutainer, Becton, Dickinson,
Plymouth, United Kingdom) and exposed to 1  107 CFU/ml ΔpblB or WT pneumococci for 30 min at
37°C. Subsequently, either medium, PenG (0.0125 g/ml), CPX (0.533 g/ml), or a combination of PenG
and CPX was added, and samples were incubated for 2 h at 37°C. RNA isolation and qRT-PCR were
performed as described in the previous section. These whole-blood samples were also collected for
measurement of platelet activation and platelet-monocyte complex (PMC) by ﬂow cytometry.
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Measurement of platelet activation and PMC formation by ﬂow cytometry. Platelet activation
was measured by whole-blood ﬂow cytometry as previously described (43) by quantifying the platelet
membrane expression of the -granule protein P-selectin (CD62P) and the binding of ﬁbrinogen to the
activated IIb3 receptor (GPIIbIIIa complex). The following antibodies were used to incubate samples
from the whole-blood ex vivo assay: phycoerythrin (PE)-labeled anti-CD62P (Bio-Legend, San Diego, CA),
ﬂuorescein isothiocyanate (FITC)-labeled antiﬁbrinogen (F0111-FITC; DAKO Ltd., High Wycombe, United
Kingdom), and PC7-labeled anti-CD61 (platelet glycoprotein IIIa; Beckman Coulter, Inc., Miami, FL), the
last as a platelet identiﬁcation marker. The percentages of CD62P and ﬁbrinogen in CD61-positive events
were determined. Formation of PMC was measured by incubating samples with PC7-labeled anti-CD61
and PE-labeled anti-CD14 (a glycosylphosphatidylinositol [GPI]-linked membrane glycoprotein; Bio-
Legend). After 20 min of incubation, OptiLyse B (Beckman Coulter, Inc., Fullerton, CA) was added to lyse
erythrocytes. PMC formation was determined by quantifying the mean ﬂuorescence intensity (MFI) of
CD14 cells that were also positive for the platelet identiﬁcation marker CD61. All samples were
measured using an FC500 ﬂow cytometer (Beckman Coulter, Inc.).
Statistical analyses. Results from independent experiments (involving 6 donors) were pooled, and
data are provided as means with 95% conﬁdence intervals unless otherwise stated. A generalized linear
mixed model with post hoc Bonferroni corrections was used to statistically analyze our experimental data.
In the in vitro induction of pblB in culture medium, antibiotics were analyzed as a ﬁxed effect on pblB
expression, whereas interdonor variation was analyzed as a random effect (random intercept). For the
whole-blood assay, the presence or absence of bacteria and the different antibiotics, as well as their
interactions, were analyzed as ﬁxed effects on platelet activation, and the interdonor variation was
analyzed as a random effect (random intercept). All analyses were performed using SPSS version 20
(SPSS, Chicago, IL). The level of signiﬁcance was set at a P of 0.05.
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